Literature DB >> 29223258

Fifty Years of Monocrotaline-Induced Pulmonary Hypertension: What Has It Meant to the Field?

Nicholas S Hill1, Mark N Gillespie2, Ivan F McMurtry2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29223258     DOI： 10.1016/j.chest.2017.10.007

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  15 in total

1.  Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.

Authors:  Nathane Santanna Felix; Lucas de Mendonça; Cassia Lisboa Braga; Jaqueline Soares da Silva; Cynthia Dos Santos Samary; Juliana Borges Vieira; Fernanda Cruz; Nazareth de Novaes Rocha; Gisele Zapata-Sudo; Patricia Rieken Macedo Rocco; Pedro Leme Silva
Journal:  Br J Pharmacol       Date:  2019-12-05       Impact factor: 8.739

2.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

Review 3.  The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Authors:  Olivier Boucherat; Vineet Agrawal; Allan Lawrie; Sebastien Bonnet
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

4.  Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites.

Authors:  Yisheng He; Wei Lian; Liang Ding; Xiaoyu Fan; Jiang Ma; Qing-Yu Zhang; Xinxin Ding; Ge Lin
Journal:  Arch Toxicol       Date:  2020-10-08       Impact factor: 5.153

5.  Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases.

Authors:  Rui Zhang; Yang-Yang He; Zhi-Cheng Jing
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

6.  Activation of Nicotinic Acetylcholine α7 Receptor Attenuates Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Downregulating the NLRP3 Inflammasome.

Authors:  Yan Deng; Sheng-Lan Guo; Bin Wei; Xing-Cui Gao; Ying-Chuan Zhou; Jia-Quan Li
Journal:  Front Pharmacol       Date:  2019-02-26       Impact factor: 5.810

7.  NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.

Authors:  Eamon P Mulvaney; Helen M Reid; Lucia Bialesova; Annie Bouchard; Dany Salvail; B Therese Kinsella
Journal:  BMC Pulm Med       Date:  2020-04-06       Impact factor: 3.317

8.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25

9.  Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats.

Authors:  Olga Sadowska; Marta Baranowska-Kuczko; Anna Gromotowicz-Popławska; Michał Biernacki; Aleksandra Kicman; Barbara Malinowska; Irena Kasacka; Anna Krzyżewska; Hanna Kozłowska
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

Review 10.  The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.

Authors:  Jenny L Hewes; Ji Young Lee; Karen A Fagan; Natalie N Bauer
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.